May 7th 2024
The extension trial aims to address the cognitive impairment often observed in schizophrenia.
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Real Psychiatry 2025
January 2025 - Exact Date TBA
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
He wasn’t the first person I met days before I was to start my psychiatric residency, but as I walked about in my new city, he caught my attention much more than most. As psychiatrists, we typically assume that we will hear the inside stories, even if in bits and pieces, that will help us better understand and help patients. But perhaps we are too expectant . . .
Read More
Notes From Prague: Treating Schizophrenia Beyond Antipsychotic Drugs
March 6th 2012With several good presentations going on today at EPA 2012, the hardest part was deciding which to attend. The sessions started at 8 this morning, and I decided to go to the Treating Schizophrenia Beyond Antipsychotic Drugs: Cognitive and Metacognitive Interventions.
Read More
Research Points to Shared Environmental Factors for Autism and ASD
March 2nd 2012Three twin studies published between 1977 and 1995, which provided the main body of knowledge on heritability of autism, showed a concordance rate of 72% for a total of 36 monozygotic pairs and a concordance rate of 0% for 30 dizygotic pairs.
Read More
How American Psychiatry Can Save Itself: Part 2
March 2nd 2012In this article the topic addressed are the primary reasons for the American public’s disenchantment with psychiatry; how the profession ought to address these issues; and how we need to replace the DSM’s categorical system with one that is clinically useful for both clinicians and patients.
Read More
Condemning Torture and Abuse: A Call to Action
February 29th 2012The plain fact is that nothing that has been claimed in the name of defending our country can justify cruel, inhuman, and degrading treatment of another man or woman. Torture, in any form-light or heavy-is not a tool of interrogation or useful for gathering good intelligence.
Read More
An Evidence-Based Practice of Psychoeducation for Schizophrenia
February 8th 2012Schizophrenia is often characterized by lack of insight, treatment nonadherence, and poor prognosis. However, research suggests that patients with schizophrenia benefit immensely from learning about their illness.
Read More
While research suggests that cannabis use can induce an acute psychotic state, there is controversy about whether it may precipitate psychotic disorders, such as schizophrenia. These authors offer an update on this important issue and provide clinically useful recommendations.
Read More
Is the Criticism of DSM-5 Misguided?
December 22nd 2011Critics of DSM-5 argue that the expansion of diagnostic criteria may increase the number of “mentally ill” individuals and/or pathologize “normal” behavior, and lead to the possibility that thousands-if not millions-of new patients will be exposed to medications which may cause more harm than good.
Read More
DSM-5: Petitions, Predictions, and Prescriptions
November 22nd 2011Some months ago, I received a stern admonition from my family doctor. My fasting blood sugar of 99 mg/dL was “right on the border”, he said, and I had better work on bringing it down. “But,” I protested, “when I was in medical school (in the 70s), the normal FBS range went up to 110 mg/dL!” "Well,” he replied a bit huffily, “they changed the criteria!”
Read More
Can Psychiatry be Both A Medical Science and A Healing Art? The Case for Polythetic Pluralism
October 19th 2011When I was a first-year resident, a revered supervisor of mine made the statement-half-facetiously-that, “In psychiatry, you can do biology in the morning and theology in the afternoon!”
Read More
Modeling Schizophrenia: An In Vitro Model of a Tough Disease
October 7th 2011This column has always been about the world of molecular mental health research. I revisit the technology in this column, now aimed at one of molecular neuropsychiatry’s most intractable, frustrating lines of research: the molecular/cellular basis of schizophrenia.
Read More